Trials / Completed
CompletedNCT05810116
Effectiveness of PEA Compared to Placebo on Acute Menstrual Pain
Effect of Palmitoylethanolamide (PEA) Compared to a Placebo on Acute Menstrual Pain in an Adult Population - a Double-blind, Crossover, Randomised Controlled Trial.
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 80 (actual)
- Sponsor
- RDC Clinical Pty Ltd · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a double blind, randomised, placebo-controlled trial to evaluate orally-dosed Palmitoylethanolamide (PEA) compared to placebo on menstrual pain in otherwise healthy participants 18 years and over.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Levagen+ | Daily dose of 1-2 capsules (1 capsule containing 350mg Levagen+ equivalent to 300mg PEA) |
| DRUG | Microcrystalline cellulose | Daily dose of 1-2 capsules (1 capsule containing 350mg) |
Timeline
- Start date
- 2023-05-19
- Primary completion
- 2023-12-20
- Completion
- 2023-12-20
- First posted
- 2023-04-12
- Last updated
- 2024-11-14
Locations
1 site across 1 country: Australia
Source: ClinicalTrials.gov record NCT05810116. Inclusion in this directory is not an endorsement.